Skip to main content

Table 1 Clinical characteristics

From: Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study

Items

STEMI patients (N = 1244)

Demographic characteristics

 

Age (years), mean ± SD

63.9 ± 11.9

Male, No. (%)

915 (73.6)

BMI (kg/m2), mean ± SD

25.3 ± 31.4

Medical history

 

History of diabetes mellitus, No. (%)

251 (20.2)

History of allergy, No. (%)

87 (7.0)

History of cardiac surgery, No. (%)

62 (5.0)

History of critical respiratory disease, No. (%)

36 (2.9)

History of renal function impairment, No. (%)

22 (1.8)

CRUSADE score

 

Mean ± SD

30.2 ± 14.5

Risk stratification, No. (%)

 

 Very low risk (≤ 20)

328 (26.4)

 Low risk (21–30)

350 (28.1)

 Moderate risk (31–40)

277 (22.3)

 High risk (41–50)

157 (12.6)

 Very high risk (> 50)

113 (9.1)

 Unknown

19 (1.5)

PCI characteristics

 

Operative timing, No. (%)

 

 Emergency operation

938 (75.4)

 Elective operation

306 (24.6)

Types of coronary interventional therapy, No. (%)

 

 Stent implantation

1184 (95.2)

 Balloon dilatation

56 (4.5)

 Thrombus aspiration

0 (0.0)

 Others

4 (0.3)

Types of stents, No. (%)

 

 Drug stent

1143 (91.9)

 Bare stent

42 (3.4)

 Others

1 (0.1)

 Unknown

58 (4.7)

Arterial access, No. (%)

 

 Radial artery

1180 (94.9)

 Femoral artery

61 (4.9)

 Brachial artery

0 (0.0)

 Others

3 (0.2)

Culprit vessel, No. (%)

 

 Single

1053 (84.6)

 Multiple

190 (15.3)

 Unknown

1 (0.1)

Administration of bivalirudin

 

Preoperative or intraoperative, No. (%)

44 (3.5)

Postoperative ≤ 4 h, No. (%)

1116 (89.7)

Postoperative > 4 h, No. (%)

84 (6.8)

Combined with GP IIb/IIIa inhibitors, No. (%)

805 (64.7)

  1. STEMI, ST-segment elevation myocardial infarction; SD, standard deviation; BMI, body mass indexes; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines; PCI, percutaneous coronary intervention; GP, glycoprotein